BioMarin Pharmaceutical Stock (NASDAQ:BMRN)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$66.60

52W Range

$65.35 - $99.56

50D Avg

$75.11

200D Avg

$82.86

Market Cap

$12.58B

Avg Vol (3M)

$1.81M

Beta

0.31

Div Yield

-

BMRN Company Profile


BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

3,401

IPO Date

Jul 26, 1999

Website

BMRN Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Royalty And Other$46.69M$54.01M$62.78M
Enzyme Product$1.72B--
Product$2.37B$2.04B$1.78B

Fiscal year ends in Dec 23 | Currency in USD

BMRN Financial Summary


Dec 23Dec 22Dec 21
Revenue$2.42B$2.10B$1.85B
Operating Income$157.60M$57.55M$-60.01M
Net Income$167.65M$141.56M$-64.08M
EBITDA$261.98M$159.51M$48.03M
Basic EPS$0.87$0.76$-0.35
Diluted EPS$0.87$0.75$-0.35

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Oct 29, 24 | 8:26 PM
Q2 24Aug 05, 24 | 9:35 PM
Q1 24Apr 24, 24 | 12:00 AM

Peer Comparison


TickerCompany
IONSIonis Pharmaceuticals, Inc.
INCYIncyte Corporation
ARWRArrowhead Pharmaceuticals, Inc.
MREOMereo BioPharma Group plc
APLSApellis Pharmaceuticals, Inc.
BPMCBlueprint Medicines Corporation
EXELExelixis, Inc.
HALOHalozyme Therapeutics, Inc.
DAWNDay One Biopharmaceuticals, Inc.
ALNYAlnylam Pharmaceuticals, Inc.
LEGNLegend Biotech Corporation
AGIOAgios Pharmaceuticals, Inc.
LQDALiquidia Corporation
PCVXVaxcyte, Inc.
TECHBio-Techne Corporation
KRTXKaruna Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals, Inc.